Adavosertib

DB11740InvestigationalSmall molecule

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Mechanism: Pharmacologically active on Wee1-like protein kinase
Curator reviewed
Formula / weight: C₂₇H₃₂N₈O₂ · 500.607 g/mol (avg)
Code names: AZD-1775 · MK-1775

Resolves to

Compound

UNIIK2T6HJX3I3CAS955365-80-7ChEMBLCHEMBL1976040ChEBI91414PubChem24856436

Structure

InChIKeyBKWJAKQVGHWELA-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C1

Targets

P30291WEE1

What you can answer from here — as of March 05, 2023

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

56Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Adavosertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account